The present invention provides a compound represented by formula (I) wherein a combination of X and L represents a combination wherein X represents a nitrogen atom and L represents an oxygen atom or NH, etc., n is 1 or 2, E represents a C6-C10 aryl group, etc., R.sup.1 and R.sup.2 are identical to or different from each other and each represents a C1-C3 chain hydrocarbon group which may be optionally substituted with one or more halogens, etc.]

which has an excellent control efficacy against pests, or its N-oxide or salts of the same.

##STR00001##

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

New methods and substrates are provided that include antireflective compositions that comprise one or more thermal acid generators.

New methods and substrates are provided that include antireflective compositions that comprise one or more thermal acid generators.

The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp.sup.2-sp.sup.3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a second compound comprising a substituted or unsubstituted aromatic group in the presence of a catalyst, water, and a first base. The process may find use in the preparation of active pharmaceutical ingredients.

The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp.sup.2-sp.sup.3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a second compound comprising a substituted or unsubstituted aromatic group in the presence of a catalyst, water, and a first base. The process may find use in the preparation of active pharmaceutical ingredients.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.

Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.